Received Mar 24, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | PO / MO |
Patient missed to take third dose of Vivotif yesterday; Case reference number US-BN-2024-002547 is a spontaneous case initially received from a nurse via Med Communication (reference number: USBAV24-2514) on 25-Sep-2024 and concerns a patient of unknown age and gender. The patient's medical history and concomitant medication details were not provided. On unspecified dates, the patient took the first and second dose of Vivotif (batch numbers: unknown) at an unknown dose, orally for unknown indication. As reported the patient missed to take third dose of Vivotif yesterday (explicitly coded as 'missed dose') At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif. Non-significant follow-up was downloaded from VAERS on 09-May-2025 included new reference number. Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240925-0a5ced to US-BAVARIAN NORDIC A/S-US-BN-2024-002547, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A patient of unknown age and gender took the first and the second dose of Vivotif for unknown indication. As reported the patient missed to take the third dose of Vivotif on time, which is considered as missed dose. It was unknown if the patient experienced any adverse events due to Vivotif. Product dose omission issue is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A patient of unknown age and gender took the first and the second dose of Vivotif for unknown indication. As reported the patient missed to take the third dose of Vivotif on time, which is considered as missed dose. It was unknown if the patient experienced any adverse events due to Vivotif. Product dose omission issue is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.